Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
Eduardo Mysler, Mariana Caubet, Ana Lizarraga Organización Medica de Investigación, Buenos Aires, ArgentinaCorrespondence: Eduardo Mysler Email e.mysler@omiargentina.com.arAbstract: Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profound...
Main Authors: | Mysler E, Caubet M, Lizarraga A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-06-01
|
Series: | Open Access Rheumatology : Research and Reviews |
Subjects: | |
Online Access: | https://www.dovepress.com/current-and-emerging-dmards-for-the-treatment-of-rheumatoid-arthritis-peer-reviewed-fulltext-article-OARRR |
Similar Items
-
Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01) -
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01) -
Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01) -
Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01) -
How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
by: Piet L.C.M. van Riel
Published: (2016-01-01)